Polydatin是一种活性多酚，具有多方面的好处。近年来，越来越多的研究已经注意到它对骨骼和关节疾病（BJDs）的潜在治疗效果。因此，本文回顾了Polydatin在BJDs保护作用的最新体内外进展。同时也展示了其潜在机制的洞察力。研究发现，Polydatin可以促进体外骨形成，并已揭示出在骨质疏松症、骨肉瘤、骨关节炎和风湿性关节炎动物模型中的症状改善。这些在实验室中获得的有益效果可能主要归因于Polydatin的骨代谢调节、抗炎、抗氧化、凋亡调节和自噬调节功能。然而，目前还没有关于BJDs患者的人体研究来提前发现Polydatin的临床疗效和不良反应。因此，这篇综述会作为开展临床试验的起点。此外，未来的重点还应该放在Polydatin生物利用度的低和代谢快的特质上。总之，BJDs患者中Well-designed临床试验需要Polydatin，并且必须考虑其药代动力学特性。

Polydatin is an active polyphenol displaying multifaceted benefits. Recently, growing studies have noticed its potential therapeutic effects on bone and joint disorders (BJDs). Therefore, this article reviews recent in vivo and in vitro progress on the protective role of polydatin against BJDs. An insight into the underlying mechanisms is also presented. It was found that polydatin could promote osteogenesis in vitro, and symptom improvements have been disclosed with animal models of osteoporosis, osteosarcoma, osteoarthritis, and rheumatic arthritis. These beneficial effects obtained in laboratory could be mainly attributed to the bone metabolism-regulating, anti-inflammatory, antioxidative, apoptosis-regulating, and autophagy-regulating functions of polydatin. However, studies on human subjects with BJDs that can lead to early identification of the clinical efficacy and adverse effects of polydatin have not been reported yet. Accordingly, this review would serve as a starting point for pursuing clinical trials. Additionally, future emphasis should also be devoted to the low bioavailability and prompt metabolism nature of polydatin. In summary, well-designed clinical trials of polydatin in BJD patients are in demand, and its pharmacokinetic nature must be taken into account.